Author Topic: (AAN abst.) Impact of Tysabri switch to moderate vs. high-efficacy DMT  (Read 43 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8520
  • MS diagnosed 1980
  • Location: Pacific Northwest
Abstract of a paper presented at the annual AAN conference (Philadelphia, May 4-10, 2019) by researchers at the Cleveland Clinic entitled "Early Impact of Natalizumab Switch to Moderate Versus High Efficacy Disease Modifying Therapy in Clinical Practice":


http://indexsmart.mirasmart.com/AAN2019/PDFfiles/AAN2019-000892.pdf
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
20 Views
Last post April 17, 2019, 02:42:04 pm
by agate
1 Replies
21 Views
Last post May 29, 2020, 09:45:07 pm
by agate
0 Replies
6 Views
Last post March 22, 2020, 02:55:01 pm
by agate
1 Replies
11 Views
Last post April 10, 2020, 08:35:06 pm
by agate
0 Replies
14 Views
Last post July 08, 2020, 08:37:07 pm
by agate